ALMIA Submits Comments to HHS Healthcare Advisory Committee on Medicare Advantage Broker Policy

ALMIA submitted comments ahead of the HHS Healthcare Advisory Committee’s November 9 meeting, arguing that licensed Medicare Advantage agents help beneficiaries compare plans and that a fiduciary designation could raise costs or reduce access to assistance. The group said agents receive a higher commission only for a beneficiary’s first year in Medicare Advantage, while plan switches earn the lower renewal commission; it also said CPI-linked commissions would have exceeded CMS’s actual rates in every year from 2022 to 2025. ALMIA cited carrier market exits and reduced service areas, particularly in rural and urban areas, as increasing the need for agents.

Analysis

This is an advocacy signal, not evidence that HHS will change compensation rules. The market-relevant risk is whether the committee’s discussion becomes a proposal that raises compliance costs or reduces agent compensation: that could pressure independent Medicare distributors’ economics and accelerate consolidation, while also making it harder for smaller or regionally focused plans to reach beneficiaries. Large insurers could initially save on acquisition costs, but any savings may be offset if weaker distribution reduces enrollment or pushes more members toward plans with stronger direct-sales infrastructure. The overlooked second-order effect is access: if carriers continue narrowing service areas, reducing agent capacity could compound the difficulty of enrolling rural, low-income, and higher-support beneficiaries—not simply shift sales to a cheaper channel.

Near term, the November 9 meeting is a procedural catalyst; comments from ALMIA, whose members have a commercial interest in preserving the current model, should not be treated as independent evidence of beneficiary outcomes. Over 1–3 months, watch for committee recommendations and any CMS proposal specifying fiduciary duties, compensation limits, or enforcement. Over 6–18 months, a material rule change could favor scaled agencies and insurers with established direct channels, while pressuring smaller brokers. The thesis weakens if the committee recommends no compensation changes, CMS preserves existing economics, or carriers expand agent-supported market availability. Given the low signal and absence of a proposed rule or quantified exposure, there is no compelling directional trade today.

Key Decisions for Investors

• No immediate position based on this release alone; treat the November 9 meeting as a monitoring event, not a policy outcome.
• Track SelectQuote, eHealth, and other Medicare distribution businesses for any disclosed revenue or enrollment sensitivity to agent compensation, compliance costs, and plan exits. Verify each company’s actual Medicare exposure before trading; ALMIA membership does not establish consolidated-company impact.
• Monitor large Medicare Advantage carriers for service-area changes, broker-channel dependence, and enrollment trends. Lower commissions could benefit acquisition costs only if enrollment and retention do not deteriorate.
• Escalate to a trade review if committee recommendations or a CMS proposal materially changes agent compensation or duties; falsify the negative-distributor thesis if policy remains unchanged or subsequent disclosures show stable enrollment and distribution costs.